title: Effects of cytokine-induced killer cell treatment in colorectal cancer patients: a retrospective study.
abstract: Cytokine-induced killer (CIK) cells are ex vivo generated heterogeneous NK-like T-lymphocytes, which have anti-tumor effects in vitro and in vivo. This present study was conducted to evaluate the effects of autologous CIK cell immunotherapy on the prognosis of colorectal cancer patients. Progression-free survival (PFS), overall survival (OS) and immune cells were assessed. We found that the percentages of CD8(+), CD3(+) CD56(+), CD3(-) CD56(+) cell subsets were significantly increased from 19.7±6.3%, 13.8±7.9%, 1.0±1.2% to 35.8±11.6% (P<0.001), 20.9±12.5 (P<0.001), 14.4±9.5% (P<0.001), respectively in the CIK group after 14 days of incubation. The median PFS and median OS in the CIK group were 25.8 months and 41.3 months respectively, while 12.0 months and 30.8 months in the control group. The PFS and OS curves of the CIK group and control group indicated that there were also statistically differences between two groups in PFS (log-rank, P=0.01) and OS (log-rank, P=0.037). Our results indicate that CIK cell immunotherapy in combination with chemotherapy can reduce the recurrence rate and promote the survival time of patients with colorectal cancer.
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 300, GuangZhou Road, Nanjing 210029, China.
authors.forename: Jinying
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 300, GuangZhou Road, Nanjing 210029, China.
authors.forename: Lingjun
authors.initials: L
authors.lastname: Zhu
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 300, GuangZhou Road, Nanjing 210029, China.
authors.forename: Qian
authors.initials: Q
authors.lastname: Zhang
authors.affiliation: Nanjing Medical Insurance Billing Management Center, Nanjing, China.
authors.forename: Xiang
authors.initials: X
authors.lastname: He
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 300, GuangZhou Road, Nanjing 210029, China.
authors.forename: Yongmei
authors.initials: Y
authors.lastname: Yin
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 300, GuangZhou Road, Nanjing 210029, China.
authors.forename: Yanhong
authors.initials: Y
authors.lastname: Gu
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 300, GuangZhou Road, Nanjing 210029, China.
authors.forename: Renhua
authors.initials: R
authors.lastname: Guo
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 300, GuangZhou Road, Nanjing 210029, China.
authors.forename: Kaihua
authors.initials: K
authors.lastname: Lu
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 300, GuangZhou Road, Nanjing 210029, China.
authors.forename: Lianke
authors.initials: L
authors.lastname: Liu
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 300, GuangZhou Road, Nanjing 210029, China.
authors.forename: Ping
authors.initials: P
authors.lastname: Liu
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 300, GuangZhou Road, Nanjing 210029, China. Electronic address: shuyongqian@csco.org.cn.
authors.forename: Yongqian
authors.initials: Y
authors.lastname: Shu
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069287:Capecitabine; D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy*; D055612:Cytokine-Induced Killer Cells / Q000276:immunology / Q000637:transplantation*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D002955:Leucovorin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D010071:Oxaloacetates; D012189:Retrospective Studies
chemical_list: D009944:Organoplatinum Compounds; D010071:Oxaloacetates; D003841:Deoxycytidine; D000069287:Capecitabine; D002955:Leucovorin; D005472:Fluorouracil
keywords: Colorectal cancer; Cytokine-induced killer cells; Immunotherapy; Prognosis